Table 1.
Distribution of germline or somatic BRCA1/2 variants in 507 breast cancer patients.
Table 2.
A comparison between clinical characteristics of germline BRCA1/2 variant carriers and non-carriers.
Table 3.
A comparison between clinical characteristics of patients with somatic BRCA1/2 variants and non-carriers.
Fig 1.
Impact of BRCA1/2 P/LP variants on the DFS of BC patients with stage 0~III.
Kaplan-Meier survival analysis; P values calculated using a log-rank analysis. Estimated DFS of breast cancer patients with stage 0~III by BRCA status: (A) BRCA1/2 P/LP variants (germline or somatic); (B) BRCA1 and BRCA2 P/LP variants (germline or somatic); (C) Germline and somatic BRCA1/2 P/LP variants; (D) Germline BRCA1 and germline BRCA2 P/LP variants.
Table 4.
Impact of BRCA1/2 P/LP variants and other variables on the DFS and OS of breast cancer patients (Stage 0~III).
Fig 2.
Impact of BRCA1/2 P/LP variants on the DFS of subgroups with early stage.
Kaplan-Meier survival analysis; P values calculated using a log-rank analysis. Estimated DFS of breast cancer patients with stage 0~II by BRCA status: (A) BRCA1 and BRCA2 P/LP variants (germline or somatic); (B) Germline BRCA1 and BRCA2 P/LP variants. Estimated DFS of breast cancer patients with node negative disease by BRCA status: (C) BRCA1 and BRCA2 P/LP variants (germline or somatic); (D) Germline BRCA1 and BRCA2 P/LP variants.
Table 5.
Impact of BRCA1/2 P/LP variants on the DFS of breast cancer patients from subgroups of stage 0~II and III.
Table 6.
Impact of BRCA1/2 P/LP variants on the DFS of breast cancer patients from subgroups of N0 and N1~3.